#FATIGUE AFTER PFIZER FIRST DOSE TRIAL#

No new safety issues were observed, and danuglipron was not associated with increased liver enzymes like Pfizer's other discontinued weight loss pill.ĭata from the phase two trial will be presented at a future scientific conference or published in a peer-reviewed journal. More than 50% of patients across all dose sizes stopped taking the pill, compared to roughly 40% among those on the placebo, according to Pfizer. The company said high rates of adverse events were observed among patients in the study, with up to 73% experiencing nausea, up to 47% vomiting and up to 25% experiencing diarrhea. When adjusting for the difference between the weight gain observed in patients who took the placebo, Pfizer's twice-daily pill caused 8% to 13% weight loss on average at 32 weeks and 5% to 9.5% at 26 weeks. Meanwhile, patients on a placebo gained 1.4% of their body weight at 32 weeks and 0.17% at 26 weeks. Patients who took the pill twice a day lost 6.9% to 11.7% of their body weight on average at 32 weeks, and from 4.8% to 9.4% at 26 weeks. Pfizer said the trial on danuglipron met the primary goal of demonstrating 'statistically significant' reductions in body weight. Like Novo Nordisk's Wegovy and Ozempic, Pfizer's pill works by mimicking a hormone produced in the gut called GLP-1, which signals to the brain when a person is full. The trial examined the drug's effect on weight loss after 26 or 32 weeks, at different dosage amounts ranging from 40 milligrams to 200 milligrams. Pfizer's phase two trial on its twice-daily pill followed around 600 obese adults who did not have Type 2 diabetes.

The company is betting on a successful weight loss pill to help it rebound from plummeting demand for its Covid products and a roughly 40% share price drop this year.īut investors have been pessimistic about Pfizer's potential in the weight loss drug space since the company scrapped a different once-daily pill in June and proceeded with the less attractive danuglipron. Now, Friday's data puts Pfizer even further behind the dominant players in the weight loss drug market, Eli Lilly and Novo Nordisk, which are racing to develop pill versions of their blockbuster weight loss and diabetes injections. Still, the data on the twice-daily drug is a blow to Pfizer's hopes to win a $10 billion slice of the booming weight loss drug market, which CEO Albert Bourla has said could grow to $90 billion. Shares of Pfizer closed 5% lower Friday after it announced the trial results. 'At this time, twice-daily danuglipron formulation will not advance into Phase 3 studies,' the company said.īut Pfizer said it still plans to release data on a once-a-day version of the drug in the first half of 2024, which will 'inform a path forward.' The pharmaceutical giant will wait to see that data before deciding whether to start a phase three study on the once-daily pill, which Wall Street views as the more competitive form of the treatment. Personal Loans for 670 Credit Score or Lower Personal Loans for 580 Credit Score or Lower

Best Debt Consolidation Loans for Bad Credit

Fatigue after pfizer first dose